Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/340258
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampBahamondes, Luis Guillermo-
dc.typeArtigopt_BR
dc.titleEfficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system : results of two multicentre, open-label, single-arm, phase 3 trialspt_BR
dc.contributor.authorArcher, David F.-
dc.contributor.authorMerkatz, Ruth B.-
dc.contributor.authorBahamondes, Luis-
dc.contributor.authorWesthoff, Carolyn L.-
dc.contributor.authorDarney, Philip-
dc.contributor.authorApter, Dan-
dc.contributor.authorJensen, Jeffrey T.-
dc.contributor.authorBrache, Vivian-
dc.contributor.authorNelson, Anita L.-
dc.contributor.authorBanks, Erika-
dc.contributor.authorBartfai, Gyorgy-
dc.contributor.authorPortman, David J.-
dc.contributor.authorPlagianos, Modena-
dc.contributor.authorDart, Clint-
dc.contributor.authorKumar, Narender-
dc.contributor.authorCreasy, George W.-
dc.contributor.authorSitruk-Ware, Regine-
dc.contributor.authorBlithe, Diana L.-
dc.subjectAnticoncepcionaispt_BR
dc.subject.otherlanguageContraceptive devicespt_BR
dc.description.abstractA ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive vaginal system and return to menses or pregnancy after use. In two identically designed, multicentre, open-label, single-arm, phase 3 trials (one at 15 US academic and community sites and one at 12 US and international academic and community sites), participants followed a 21-days-in, 7-days-out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycles. Participants were healthy, sexually active, non-pregnant, non-sterilised women aged 18-40 years. Women were cautioned that any removals during the 21 days of cyclic use should not exceed 2 h, and used daily paper diaries to record vaginal system use. Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index for women aged 35 years and younger, excluding adjunctive contraception cycles, as the primary efficacy outcome measure. We also did intention-to-treat Kaplan-Meier life table analyses and followed up women who did not use hormonal contraceptives or desired pregnancy after study completion for 6 months for return to menses or pregnancy. The trials are registered with ClinicalTrials.gov, numbers NCT00455156 and NCT00263341. Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites, and between Nov 1, 2006, and July 2, 2009, at the 12 US and international sites we enrolled 2278 women. Our overall efficacy analysis included 2265 participants (1130 in the US study and 1135 in the international study) and 1303 (57.5%) participants completed up to 13 cycles. The Pearl Index for the primary efficacy group was 2.98 (95% CI 2.13-4.06) per 100 woman-years, and was well within the range indicative of efficacy for a contraceptive under a woman's control. The Kaplan-Meier analysis revealed the contraceptive vaginal system was 97.5% effective, which provided further evidence of efficacy. Pregnancy occurrence was similar across cycles. All 290 follow-up participants reported return to menses or became pregnant (24 [63%] of 38 women who desired pregnancy) within 6 months. Interpretation The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contraceptive for 13 consecutive cycles of use. This new product adds to the contraceptive method mix and the 1-year duration of use means that women do not need to return to the clinic or pharmacy for refills every few monthspt_BR
dc.relation.ispartofThe lancet global healthpt_BR
dc.relation.ispartofabbreviationLancet glob. healthpt_BR
dc.publisher.cityLondonpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherElsevierpt_BR
dc.date.issued2019-
dc.date.monthofcirculationAug.pt_BR
dc.language.isoengpt_BR
dc.description.volume7pt_BR
dc.description.issuenumber8pt_BR
dc.description.firstpagee1054pt_BR
dc.description.lastpagee1064pt_BR
dc.rightsAbertopt_BR
dc.sourceWOSpt_BR
dc.identifier.eissn2214-109Xpt_BR
dc.identifier.doi10.1016/S2214-109X(19)30265-7pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S2214109X19302657pt_BR
dc.date.available2020-05-06T16:21:46Z-
dc.date.accessioned2020-05-06T16:21:46Z-
dc.description.provenanceSubmitted by Mariana Aparecida Azevedo (mary1@unicamp.br) on 2020-05-06T16:21:46Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-08-27T19:16:36Z : No. of bitstreams: 1 000474823700029.pdf: 443915 bytes, checksum: a034d0e51df7033d4c774e5a73e1985f (MD5)en
dc.description.provenanceMade available in DSpace on 2020-05-06T16:21:46Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/340258-
dc.contributor.departmentDepartamento de Tocoginecologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.identifier.source000474823700029pt_BR
dc.creator.orcid0000-0002-7356-8428pt_BR
dc.type.formArtigopt_BR
dc.description.sponsorNoteWe thank The Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NICHD), the US Agency for International Development (USAID), and WHO for funding the phase 3 studies. We also acknowledge all participating study investigators (appendix p 1) and coordinators at the 27 clinical sites for conduct of the two phase 3 clinical trials and the over 2200 women participants from eight countries. We further acknowledge the medical writing assistance of Kathleen Ohleth (Precise Publications; Bedminster. NJ, USA) supported by TherapeuticsMD (Boca Raton, FL, USA). The NICHD (contract no HHSN27500403372) funded and conducted the US study and USAID (grant no GPO-A-00-04-00019-00) funded the international study, which was conducted by the Population Council. WHO Department of Reproductive Health and Research funded two international study sites. Medical writing support for manuscript submission and resubmission was supported by TherapeuticsMD. The authors acknowledge the major contribution of Daniel R Mishell Jr (deceased), from the Department of Obstetrics and Gynecology, University of Southern California, Keck School of Medicine (Los Angeles, CA, USA) who invented the concept of the vaginal system to deliver contraceptive steroids, did many of the clinical studies for the segesterone acetate and ethinylestradiol contraceptive vaginal system, and was a principle investigator for the 300 B phase 3 study analysed in this Article while a member of the International Committee for Contraceptive Research (ICCR) of the Population Council. The authors also gratefully acknowledge the contribution of Horacio B Croxatto, from the University of Chile (Santiago, Chile), who established the clinical centre in Chile, participated in all pivotal clinical studies for this ring, and provided guidance for the full development of this new contraceptive while a member of the ICCRpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000474823700029.pdf433.51 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.